192 related articles for article (PubMed ID: 18392053)
21. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
23. The discovery and mechanism of action of letrozole.
Bhatnagar AS
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):7-17. PubMed ID: 17912633
[TBL] [Abstract][Full Text] [Related]
24. Initialization of adjuvant hormonal treatment for breast cancer.
Martínez Guisado A; Sánchez Muñoz A; de la Cabeza Lomas Garrido M; Ruíz Borrego M; Bayo Calero J; de Toro Salas R; González Mancha R; de la Haba Rodríguez J; Alba Conejo E
Adv Ther; 2011 Sep; 28 Suppl 6():66-84. PubMed ID: 21922396
[TBL] [Abstract][Full Text] [Related]
25. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
26. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
Viola G; Sergi D; Conti F; Lopez M
Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
[TBL] [Abstract][Full Text] [Related]
27. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Chirgwin J; Sun Z; Smith I; Price KN; Thürlimann B; Ejlertsen B; Bonnefoi H; Regan MM; Goldhirsch A; Coates AS;
Breast Cancer Res Treat; 2012 Jan; 131(1):295-306. PubMed ID: 21892704
[TBL] [Abstract][Full Text] [Related]
28. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Bell LN; Nguyen AT; Li L; Desta Z; Henry NL; Hayes DF; Wolff AC; Stearns V; Storniolo AM; Flockhart DA;
J Clin Pharmacol; 2012 Dec; 52(12):1852-60. PubMed ID: 22174434
[TBL] [Abstract][Full Text] [Related]
29. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
30. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
31. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
32. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
[TBL] [Abstract][Full Text] [Related]
33. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
[TBL] [Abstract][Full Text] [Related]
34. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy.
Mourits MJ; Böckermann I; de Vries EG; van der Zee AG; ten Hoor KA; van der Graaf WT; Sluiter WJ; Willemse PH
Br J Cancer; 2002 May; 86(10):1546-50. PubMed ID: 12085202
[TBL] [Abstract][Full Text] [Related]
36. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
[TBL] [Abstract][Full Text] [Related]
37. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
38. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Phillips KA; Ribi K; Sun Z; Stephens A; Thompson A; Harvey V; Thürlimann B; Cardoso F; Pagani O; Coates AS; Goldhirsch A; Price KN; Gelber RD; Bernhard J
Breast; 2010 Oct; 19(5):388-95. PubMed ID: 20385495
[TBL] [Abstract][Full Text] [Related]
39. The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Smith IE; Yeo B; Schiavon G
Am Soc Clin Oncol Educ Book; 2014; ():e16-24. PubMed ID: 24857098
[TBL] [Abstract][Full Text] [Related]
40. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
